Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04893018 · ClinicalTrials.gov registry record · Phase 1
NT-I7 for Kaposi Sarcoma in Patients With or Without HIV
A Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT04893018 is a Phase 1 study that was terminated before completion, run by Fred Hutchinson Cancer Center. The registered enrollment target is 8 participants.
The verdict
NCT04893018, a Phase 1 study, was terminated before completion, sponsored by Fred Hutchinson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This phase I trial studies the best dose and effects of NT-I7 in treating Kaposi sarcoma in patients with or without HIV. NT-I7 works by using a patient's immune system to fight cancer. It is made in a laboratory and is used to boost, direct, or restore the body's natural defenses against cancer. NT-I7 may work better in treating Kaposi sarcoma.
Interventions
- BIOLOGICAL Efineptakin alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2022-05-23 |
| Est. Completion | 2023-12-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04893018
The ClinicalTrials.gov registry entry for NCT04893018 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Efineptakin alfa is the first listed.
NCT04893018 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04893018 about?
NCT04893018 is a clinical study titled "NT-I7 for Kaposi Sarcoma in Patients With or Without HIV". This phase I trial studies the best dose and effects of NT-I7 in treating Kaposi sarcoma in patients with or without HIV. NT-I7 works by using a patient's immune system to fight cancer. It is made in a laboratory and is used to boost, direct, or restore the body's natural defenses against cancer. NT...
What is the current status of trial NCT04893018?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2022-05-23. Estimated completion is 2023-12-15.
What interventions are being tested in trial NCT04893018?
The interventions under investigation include: Efineptakin alfa (BIOLOGICAL).
Who is sponsoring clinical trial NCT04893018?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.